1Diaconu CC, Szathmari M, Keri G, et al. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232[J]. Br J Cancer, 1999,80 : 1197-1203.
2Nakaizumi A, Uehara H, Baba M, et al. Inhibition by somatostatin of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats [ J ]. Carcinogenesis, 1993, 14:2601-2604.
3Davies N, Yates J, Kynaston H, et al. Effects of octreotide on liver regeneration and tumour growth in the regenerating liver[J]. J Gastroenterol Hepatol, 1997,12: 47-53.
4Schindel DT, Grosfeld JL. Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide[J]. J Pediatr Surg, 1997, 32: 995-998.
5Slooter GD, Breeman WA, Marquet RL, et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver[J]. Int J Cancer, 1999,81 : 767-771.
6Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas[J]. Gut,1999,45: 766-774.
7Rabinowitz I, Telepak R, Lee FC. et al. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma [J]. Clin Nucl Med, 2002,27: 499-502.
8Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest,by human somatostatin receptor 3 [J]. Mol Endocrinol,1996,10: 1688-1696.
9Teijeiro R, Rios R, Costoya JA, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53[J]. Cell Physiol Biochem, 2002,12: 31-33.
10Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study[J]. Gut, 1998,42 : 442-447.
6Zayour DH,Selman WR,Arafah BM. Extreme elevation of intrasellar pressure in patients with pituitary tumor apoplexy: relation to pituitary function. JCEM 2004, 89 :5649-5654.
7Johansson M, McKay JD . Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk[ J ]. Cancer Epidemiol Biomark Prey,2009,18 (5) :223-225.
8Verhoef C, van-Dekken H. Somatostatin receptor in human hepatocellular carcinomas : biological, patient and tumor characteristics [ J]. Dig Surg,2008,25 ( 1 ) :45-47.
9Samonakis DN, Notas G, Christodoulakis N, et al. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken [ J ]. Dig Dis Sci, 2008,53 (9) :338 -241.
